Pharmacokinetics
Help Questions
USMLE Step 1 › Pharmacokinetics
A 70-year-old man with atrial fibrillation is taking oral warfarin (stable INR 2.3). He begins trimethoprim-sulfamethoxazole for a urinary tract infection. Four days later, he presents with epistaxis and gingival bleeding. Labs: INR 6.1, hemoglobin 12.8 g/dL, creatinine 1.0 mg/dL, AST 28 U/L, ALT 24 U/L, albumin 4.1 g/dL. Warfarin is highly albumin-bound and primarily cleared by hepatic metabolism; its half-life is ~36 hours. The clinician suspects a drug-drug interaction affecting clearance and/or free fraction. Which of the following best describes how the pharmacokinetics of warfarin is altered in this patient?
Reduced absorption decreases bioavailability, increasing INR due to higher potency
Enzyme inhibition decreases hepatic clearance, increasing AUC and prolonging effective half-life
Enzyme induction increases clearance, decreasing AUC and lowering INR
Increased Vd decreases free drug and reduces bleeding risk despite higher INR
Explanation
This question tests the application of pharmacokinetics in clinical scenarios, specifically understanding how pharmacokinetic parameters affect drug dosing and efficacy. Pharmacokinetics involves absorption, distribution, metabolism, and excretion (ADME) of drugs. Key parameters include half-life, volume of distribution, and clearance. In this case, warfarin bleeding from interaction with trimethoprim-sulfamethoxazole arises from enzyme inhibition, illustrating reduced clearance elevating INR. The correct answer, A, is based on inhibition decreasing clearance and increasing AUC, showing why anticoagulation intensifies. A common misconception is enzyme induction increasing clearance, as seen in B, which fails because this interaction inhibits metabolism. To teach this, focus on CYP interactions and monitoring. Encourage students to predict interaction outcomes using kinetic principles.
A 60-year-old woman with primary biliary cholangitis and cirrhosis is started on oral morphine for severe pain. Within 24 hours she becomes increasingly sedated with shallow respirations. Exam: RR 8/min, pinpoint pupils. Labs: total bilirubin 6.0 mg/dL, albumin 2.4 g/dL, INR 2.0, creatinine 0.9 mg/dL. Morphine has significant first-pass metabolism; hepatic clearance contributes substantially to elimination, and normal half-life is ~2–3 hours. The team reviews that impaired hepatic metabolism can increase bioavailability and reduce clearance, leading to higher plasma concentrations at a given dose. Which pharmacokinetic parameter is most affected by liver disease in this patient?
Decreased hepatic clearance and reduced first-pass metabolism increasing systemic exposure
Decreased Vd causing lower peak concentrations and less respiratory depression
Increased clearance leading to reduced AUC and decreased sedation risk
Increased renal elimination shortening half-life and preventing accumulation
Explanation
This question tests the application of pharmacokinetics in clinical scenarios, specifically understanding how pharmacokinetic parameters affect drug dosing and efficacy. Pharmacokinetics involves absorption, distribution, metabolism, and excretion (ADME) of drugs. Key parameters include half-life, volume of distribution, and clearance. In this case, the patient with cirrhosis shows morphine oversedation from increased exposure, illustrating impaired hepatic clearance and reduced first-pass. The correct answer, B, is based on decreased clearance increasing systemic exposure, showing why respiratory depression ensues. A common misconception is increased clearance reducing AUC, as seen in A, which fails because cirrhosis impairs metabolism. To teach this, focus on opioid kinetics in liver disease. Encourage students to review extraction ratios and monitor for accumulation.
A 66-year-old woman with chronic kidney disease (CKD) stage 4 presents with pneumonia and is started on intravenous gentamicin. She weighs 60 kg. Labs: creatinine 2.6 mg/dL, BUN 46 mg/dL, estimated GFR 22 mL/min/1.73 m$^2$, AST 24 U/L, ALT 20 U/L. Gentamicin is hydrophilic with Vd $\approx 0.25\ \text{L/kg}$ and is eliminated almost entirely by glomerular filtration; normal half-life is ~2 hours with normal renal function. Twelve hours after a standard dose, the measured concentration remains elevated. How would renal impairment alter the elimination of this drug?
Decreased renal clearance prolongs half-life, increasing trough concentrations and accumulation risk
Renal impairment primarily decreases Vd, lowering peak concentrations after IV dosing
Renal impairment increases first-pass metabolism, reducing AUC and toxicity risk
Decreased renal clearance shortens half-life because less drug is filtered into urine
Explanation
This question tests the application of pharmacokinetics in clinical scenarios, specifically understanding how pharmacokinetic parameters affect drug dosing and efficacy. Pharmacokinetics involves absorption, distribution, metabolism, and excretion (ADME) of drugs. Key parameters include half-life, volume of distribution, and clearance. In this case, elevated gentamicin levels in CKD result from impaired excretion, illustrating reduced renal clearance. The correct answer, A, is based on decreased clearance prolonging half-life and raising troughs, showing ototoxicity risk. A common misconception is shortened half-life from reduced clearance, as seen in B, which fails because lower clearance extends half-life. To teach this, focus on GFR-drug clearance relationships. Encourage students to use nomograms for dosing.
A 72-year-old man with heart failure and CKD stage 3 is taking digoxin for rate control. He presents with nausea, yellow-green vision changes, and frequent premature ventricular contractions. Labs: creatinine 1.9 mg/dL, estimated GFR 35 mL/min/1.73 m$^2$, potassium 3.1 mmol/L, magnesium 1.5 mg/dL, digoxin level 2.6 ng/mL (therapeutic 0.5–0.9). Digoxin has Vd $\approx 7\ \text{L/kg}$ and is primarily renally cleared; normal half-life is ~36 hours, longer in renal impairment. What adjustment to the dosing regimen is most appropriate given the pharmacokinetic data?
Increase the maintenance dose to overcome reduced distribution in CKD
No change is needed because Vd determines clearance for renally eliminated drugs
Decrease the maintenance dose and/or extend the dosing interval due to reduced renal clearance
Shorten the dosing interval to reach steady state sooner despite prolonged half-life
Explanation
This question tests the application of pharmacokinetics in clinical scenarios, specifically understanding how pharmacokinetic parameters affect drug dosing and efficacy. Pharmacokinetics involves absorption, distribution, metabolism, and excretion (ADME) of drugs. Key parameters include half-life, volume of distribution, and clearance. In this case, digoxin toxicity in CKD stems from accumulation, illustrating prolonged half-life from reduced renal clearance. The correct answer, B, is based on decreasing dose or interval to prevent toxicity, showing adjustment needs. A common misconception is increasing dose for reduced distribution, as seen in A, which fails because Vd is unchanged in CKD. To teach this, focus on renal dosing principles. Encourage students to monitor levels and electrolytes.
A 50-year-old man with type 2 diabetes and CKD stage 5 (on hemodialysis) develops a skin infection and is prescribed oral trimethoprim-sulfamethoxazole. Two days later he becomes lethargic and confused. Labs: creatinine 6.8 mg/dL, BUN 78 mg/dL, potassium 5.8 mmol/L, bicarbonate 18 mmol/L. The drug is partially renally eliminated and has a normal half-life of ~10 hours; in severe renal impairment, clearance falls and half-life increases substantially. Which pharmacokinetic parameter is most affected by renal failure in this patient?
Decreased Vd causing faster elimination and reduced adverse effects
Decreased clearance leading to increased half-life and higher steady-state concentrations
Decreased bioavailability due to uremia reducing intestinal absorption and AUC
Increased renal clearance causing decreased AUC and subtherapeutic exposure
Explanation
This question tests the application of pharmacokinetics in clinical scenarios, specifically understanding how pharmacokinetic parameters affect drug dosing and efficacy. Pharmacokinetics involves absorption, distribution, metabolism, and excretion (ADME) of drugs. Key parameters include half-life, volume of distribution, and clearance. In this case, trimethoprim-sulfamethoxazole toxicity in ESRD arises from accumulation, illustrating decreased clearance in renal failure. The correct answer, B, is based on reduced clearance increasing half-life and concentrations, showing metabolic acidosis risk. A common misconception is increased clearance reducing AUC, as seen in A, which fails because renal impairment impairs excretion. To teach this, focus on half-life changes in CKD. Encourage students to adjust for GFR.
A 39-year-old man with bipolar disorder is taking lithium. He develops dehydration from gastroenteritis and continues his usual dose. He presents with tremor, ataxia, and confusion. Labs: creatinine 1.8 mg/dL (baseline 0.9), BUN 38 mg/dL, sodium 150 mmol/L, lithium level 2.1 mmol/L (therapeutic 0.6–1.2). Lithium is not metabolized and is eliminated by renal excretion; reduced GFR decreases clearance and prolongs half-life. How would renal impairment alter the elimination of this drug?
Renal impairment increases first-pass metabolism, lowering lithium levels
Renal impairment decreases Vd, which directly increases clearance and prevents toxicity
Decreased renal clearance prolongs half-life, increasing steady-state concentration at the same dose
Decreased renal clearance shortens half-life by reducing tubular reabsorption
Explanation
This question tests the application of pharmacokinetics in clinical scenarios, specifically understanding how pharmacokinetic parameters affect drug dosing and efficacy. Pharmacokinetics involves absorption, distribution, metabolism, and excretion (ADME) of drugs. Key parameters include half-life, volume of distribution, and clearance. In this case, lithium toxicity from dehydration-induced AKI shows impaired excretion, illustrating reduced clearance in renal impairment. The correct answer, A, is based on decreased clearance prolonging half-life and raising levels, showing neurotoxicity. A common misconception is shortened half-life from reduced clearance, as seen in B, which fails because lower clearance extends half-life. To teach this, focus on hydration and monitoring in lithium use. Encourage students to correlate GFR with levels.
A 67-year-old man with CKD stage 4 is started on oral gabapentin for neuropathic pain. After 1 week, he reports profound sedation and dizziness. Labs: creatinine 2.8 mg/dL, estimated GFR 20 mL/min/1.73 m$^2$, AST 18 U/L, ALT 16 U/L. Gabapentin is not significantly metabolized and is eliminated unchanged by the kidneys; normal half-life is ~5–7 hours but increases markedly when GFR is reduced. Which of the following best describes how the pharmacokinetics of gabapentin is altered in this patient?
Vd decreases and therefore clearance increases, preventing accumulation
Half-life is shortened due to decreased filtration, reducing exposure and efficacy
Half-life is prolonged due to reduced renal clearance, increasing AUC at the same dose
Bioavailability increases because renal failure enhances intestinal absorption
Explanation
This question tests the application of pharmacokinetics in clinical scenarios, specifically understanding how pharmacokinetic parameters affect drug dosing and efficacy. Pharmacokinetics involves absorption, distribution, metabolism, and excretion (ADME) of drugs. Key parameters include half-life, volume of distribution, and clearance. In this case, gabapentin sedation in CKD stems from accumulation, illustrating prolonged half-life from reduced renal clearance. The correct answer, A, is based on extended half-life increasing AUC, showing why dosing must be reduced. A common misconception is shortened half-life from decreased filtration, as seen in B, which fails because reduced clearance prolongs half-life. To teach this, focus on renally cleared drugs in CKD. Encourage students to use dosing guidelines based on GFR.
A 24-year-old woman with epilepsy is started on intravenous phenytoin for status epilepticus and then transitioned to oral maintenance dosing. Therapeutic drug monitoring is performed. Phenytoin has Vd $\approx 0.7\ \text{L/kg}$ and is highly protein-bound; at therapeutic levels, elimination can approach capacity-limited kinetics. A concentration-time curve after IV loading shows an initial steep decline followed by a slower decline; later, small dose increases produce large concentration increases. Which pharmacokinetic parameter is most affected as phenytoin concentrations approach metabolic saturation?
Vd increases as enzymes saturate, causing faster elimination and lower AUC
Bioavailability decreases as enzymes saturate, causing higher required doses
Half-life becomes shorter as concentration increases because elimination becomes first-order
Clearance decreases as enzymes saturate, causing a disproportionate rise in steady-state concentration
Explanation
This question tests the application of pharmacokinetics in clinical scenarios, specifically understanding how pharmacokinetic parameters affect drug dosing and efficacy. Pharmacokinetics involves absorption, distribution, metabolism, and excretion (ADME) of drugs. Key parameters include half-life, volume of distribution, and clearance. In this case, phenytoin kinetics show saturation effects, illustrating capacity-limited elimination. The correct answer, A, is based on decreased clearance at saturation causing nonlinear rises, showing monitoring importance. A common misconception is increased Vd speeding elimination, as seen in B, which fails because saturation affects clearance, not Vd. To teach this, focus on Michaelis-Menten kinetics. Encourage students to plot concentration-dose relationships.
A 59-year-old man with atrial fibrillation is started on intravenous amiodarone. He later transitions to oral dosing. Amiodarone is highly lipophilic with very large Vd ($>50\ \text{L/kg}$) and a very long terminal half-life (weeks) due to extensive tissue distribution and slow release. After stopping therapy because of bradycardia, the patient continues to have drug effects for several weeks. Which pharmacokinetic parameter best explains the prolonged persistence of drug effect after discontinuation?
Very large Vd with slow redistribution prolongs terminal half-life and delays elimination
High oral bioavailability causes faster clearance and shorter terminal half-life
First-pass metabolism increases AUC and shortens time to steady state
Low protein binding increases renal filtration and rapidly clears the drug
Explanation
This question tests the application of pharmacokinetics in clinical scenarios, specifically understanding how pharmacokinetic parameters affect drug dosing and efficacy. Pharmacokinetics involves absorption, distribution, metabolism, and excretion (ADME) of drugs. Key parameters include half-life, volume of distribution, and clearance. In this case, prolonged amiodarone effects post-discontinuation arise from tissue storage, illustrating large Vd and long half-life. The correct answer, A, is based on large Vd prolonging terminal half-life, showing persistence reasons. A common misconception is high bioavailability causing faster clearance, as seen in B, which fails because bioavailability affects exposure, not elimination duration. To teach this, focus on multi-compartment models. Encourage students to consider redistribution in lipophilic drugs.
A 33-year-old woman receives a single IV bolus of a new antibiotic. Plasma concentrations are measured: 8 mg/L at 1 hour, 4 mg/L at 5 hours, and 2 mg/L at 9 hours. The drug follows first-order elimination with one-compartment kinetics and Vd $\approx 20\ \text{L}$. No renal or hepatic disease is present. Based on these data, which pharmacokinetic parameter is most directly estimated from the slope of the log concentration vs time relationship?
Maximum effect (Emax), which determines potency from dose-response curves
Elimination rate constant ($k$), which determines half-life via $t_{1/2}=0.693/k$
Bioavailability ($F$), which determines AUC after IV dosing
Volume of distribution (Vd), which equals dose divided by AUC
Explanation
This question tests the application of pharmacokinetics in clinical scenarios, specifically understanding how pharmacokinetic parameters affect drug dosing and efficacy. Pharmacokinetics involves absorption, distribution, metabolism, and excretion (ADME) of drugs. Key parameters include half-life, volume of distribution, and clearance. In this case, antibiotic concentration decline follows first-order kinetics, illustrating exponential elimination. The correct answer, A, is based on k determining half-life from log-plot slope, showing direct estimation. A common misconception is bioavailability determining IV AUC, as seen in B, which fails because F=1 for IV. To teach this, focus on one-compartment models. Encourage students to calculate k from data points.